By Fineline Cube 
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the initiation of the multi-center, randomized, double-blinded, placebo-controlled Phase III REBUILDING-2 study for its Category 1 innovative polypeptide drug candidate RAY1225 in obesity/overweight. The first subject enrollment and dosing have been completed.
Drug Profile
RAY1225 is a novel structured peptide drug with dual agonist activity targeting GLP-1 and GIP receptors. It demonstrates long-acting potential with biweekly dosing.
Clinical Progress
Previously, Phase II trials for both type 2 diabetes (T2D) and obesity/overweight have met their primary endpoints. Additionally, the drug has been cleared for two Phase III trials (SHINING-2 and SHINING-3) for T2D treatment.-Fineline Info & Tech